Actively Recruiting
Evaluating OPB-201, a Personalized T Cell Therapy for Recurrent Endometrial and Platinum-Resistant Ovarian Cancer
Led by Outpace Bio, Inc. · Updated on 2026-10-26
30
Participants Needed
5
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating OPB-201, an autologous T cell receptor T cell therapy, in participants with recurrent endometrial and platinum-resistant ovarian cancers. This phase 1ab study aims to assess the safety and find the best dose of OPB-201, which is designed to target the PRAME antigen present in tumors. The study focuses on patients who have already received prior chemotherapy treatments, including platinum-based regimens. Participants will have their own T cells collected and modified in a laboratory to create OPB-201. This therapy involves a one-time infusion administered while the participant is hospitalized. After the infusion, participants will be closely monitored frequently at the clinical site for several months to track safety and side effects. The study will also identify the maximum tolerated dose and recommended dose for future trials. During the study, participants will undergo various assessments including tumor tissue analysis and monitoring of adverse events. Researchers will evaluate treatment-emergent side effects up to two years and dose-limiting toxicities within 28 days. Participants must have measurable disease and meet specific health criteria. The total follow-up will extend to two years to observe safety outcomes and dose effects.
CONDITIONS
Brief Title
A Phase 1 Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.
Research Team
J
John Ferraro
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here